| Metric | May 2, 2024 FY24 Q2 | Jul 29, 2024 FY24 Q3 | Nov 4, 2024 FY24 Q4 | Jan 12, 2025 FY25 Q1 | May 1, 2025 FY25 Q2 | Jul 30, 2025 FY25 Q3 | Nov 3, 2025 FY25 Q4 | Jan 29, 2026 FY26 Q1 |
|---|---|---|---|---|---|---|---|---|
| For FY2025 | ||||||||
| Non-GAAP earnings per share growth relative to revenue | — | — | — | — | — | New“will grow faster than revenue” | — | — |
| Organic, constant currency revenue growth excluding COVID | — | — | — | — | — | New“mid-single-digit growth” | — | — |
| Organic, constant currency revenue growth excluding COVID | — | — | — | — | — | New“mid-single-digit growth” | — | — |
| Revenue | — | — | New“$4,150 - $4,200” | — | Lowered“$4,050 - $4,100” | Narrowed“$4,081 - $4,091” | — | — |
| Revenue | — | — | — | — | — | New“$1,030 - $1,040” | — | — |
| Revenue | — | — | — | — | New“$1,000 - $1,010” | — | — | — |
| Revenue | — | — | New“$1,025 - $1,035” | — | — | — | — | — |
| Revenue Constant Currency % Increase (Decrease) | — | — | New“2.3% to 3.5%” | — | Lowered“0.8% to 2.1%” | Narrowed“1.1% to 1.4%” | — | — |
| Revenue Constant Currency % Increase (Decrease) | — | — | — | — | — | New“3.7% to 4.7%” | — | — |
| Revenue Constant Currency % Increase (Decrease) | — | — | — | — | New“(1.0%) to (0.0%)” | — | — | — |
| Revenue Constant Currency % Increase (Decrease) | — | — | New“0.4% to 1.4%” | — | — | — | — | — |
| Revenue Organic % Increase (Decrease) | — | — | New“1.7% to 3.0%” | — | Lowered“(0.7%) to 0.5%” | Raised“(0.5%) to (0.2%)” | — | — |
| Revenue Organic % Increase (Decrease) | — | — | — | — | — | New“2.7% to 3.7%” | — | — |
| Revenue Organic % Increase (Decrease) | — | — | — | — | New“(3.5%) to (2.5%)” | — | — | — |
| Revenue Organic % Increase (Decrease) | — | — | New“(0.2%) to 0.8%” | — | — | — | — | — |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | — | — | New“3.4% to 4.7%” | — | Lowered“0.3% to 1.6%” | Narrowed“0.6% to 0.8%” | — | — |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | — | — | — | — | — | New“3.9% to 5.0%” | — | — |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | — | — | — | — | New“(2.9%) to (1.8%)” | — | — | — |
| Revenue Organic excluding COVID-19 % Increase (Decrease) | — | — | New“1.8% to 2.8%” | — | — | — | — | — |
| Revenue Reported % Increase (Decrease) | — | — | New“3.0% to 4.2%” | — | Lowered“0.5% to 1.7%” | Narrowed“1.3% to 1.5%” | — | — |
| Revenue Reported % Increase (Decrease) | — | — | — | — | — | New“4.3% to 5.3%” | — | — |
| Revenue Reported % Increase (Decrease) | — | — | — | — | New“(1.1%) to (0.1%)” | — | — | — |
| Revenue Reported % Increase (Decrease) | — | — | New“1.2% to 2.2%” | — | — | — | — | — |
| GAAP EPS | — | — | New“$3.53 - $3.63” | — | Lowered“$2.47 - $2.57” | Raised“$2.56 - $2.59” | — | — |
| GAAP EPS | — | — | — | — | — | New“$0.90 - $0.93” | — | — |
| GAAP EPS | — | — | — | — | New“$0.85 - $0.88” | — | — | — |
| GAAP EPS | — | — | New“$0.81 - $0.84” | — | — | — | — | — |
| GAAP EPS Reported % Increase (Decrease) | — | — | New“6.3% to 9.3%” | — | Lowered“(25.6%) to (22.6%)” | Raised“(22.9%) to (22.0%)” | — | — |
| GAAP EPS Reported % Increase (Decrease) | — | — | — | — | New“3.7% to 7.3%” | — | — | — |
| GAAP EPS Reported % Increase (Decrease) | — | — | New“(21.4%) to (18.4%)” | — | — | — | — | — |
| GAAP EPS, Reported % Increase (Decrease) | — | — | — | — | — | New“18.4% to 22.4%” | — | — |
| Non-GAAP EPS | — | — | New“$4.25 - $4.35” | — | Lowered“$4.15 - $4.25” | Raised“$4.23 - $4.26” | — | — |
| Non-GAAP EPS | — | — | — | — | — | New“$1.09 - $1.12” | — | — |
| Non-GAAP EPS | — | — | — | — | New“$1.04 - $1.07” | — | — | — |
| Non-GAAP EPS | — | — | New“$1.00 - $1.03” | — | — | — | — | — |
| Non-GAAP EPS Reported % Increase (Decrease) | — | — | New“4.2% to 6.6%” | — | Lowered“1.7% to 4.2%” | Raised“3.7% to 4.4%” | — | — |
| Non-GAAP EPS Reported % Increase (Decrease) | — | — | — | — | New“(1.9%) to 0.9%” | — | — | — |
| Non-GAAP EPS Reported % Increase (Decrease) | — | — | New“2.0% to 5.1%” | — | — | — | — | — |
| Non-GAAP EPS, Reported % Increase (Decrease) | — | — | — | — | — | New“7.9% to 10.9%” | — | — |
| Accelerated share repurchase (ASR) agreement | — | — | New“$250 million” | — | — | — | — | — |
| Anticipated closing of Gynesonics acquisition | — | — | New“first half of calendar year 2025” | — | — | — | — | — |
| Diluted shares outstanding | — | — | — | — | New“approximately 228 million” | Reiterated“approximately 228 million” | — | — |
| Diluted shares outstanding ( basis) | — | — | New“approximately 235 million” | — | — | — | — | — |
| Diluted shares outstanding assumption | — | — | — | — | New“approximately 228 million” | Reiterated“approximately 228 million” | — | — |
| Non-GAAP tax rate | — | — | — | — | New“approximately 19.25%” | Reiterated“approximately 19.25%” | — | — |
| Non-GAAP tax rate ( basis) | — | — | New“approximately 19.5%” | — | — | — | — | — |
| Non-GAAP tax rate assumption | — | — | — | — | New“approximately 19.25%” | Reiterated“approximately 19.25%” | — | — |
| For FY2024 | ||||||||
| Current revenue midpoint | New“$4,025 million ($4,022 million in constant currency)” | — | — | — | — | — | — | — |
| Revenue | New“$4,000 - $4,050” | Narrowed“$4,012 - $4,027” | — | — | — | — | — | — |
| Revenue | — | New“$970 - $985” | — | — | — | — | — | — |
| Revenue | New“$992.5 - $1,007.5” | — | — | — | — | — | — | — |
| Revenue Constant Currency % Increase (Decrease) | New“(0.8%) to 0.4%” | Narrowed“(0.5%) to (0.1%)” | — | — | — | — | — | — |
| Revenue Constant Currency % Increase (Decrease) | — | New“2.9% to 4.5%” | — | — | — | — | — | — |
| Revenue Constant Currency % Increase (Decrease) | New“1.2% to 2.7%” | — | — | — | — | — | — | — |
| Revenue midpoint | New“$4,025 million” | — | — | — | — | — | — | — |
| Revenue midpoint (constant currency) | New“$4,022 million” | — | — | — | — | — | — | — |
| Revenue Organic excluding COVID-19 % Increase | New“5.1% to 6.5%” | Narrowed“5.2% to 5.6%” | — | — | — | — | — | — |
| Revenue Organic excluding COVID-19 % Increase | — | New“5.0% to 6.6%” | — | — | — | — | — | — |
| Revenue Organic excluding COVID-19 % Increase | New“4.0% to 5.6%” | — | — | — | — | — | — | — |
| Revenue Reported % Increase (Decrease) | New“(0.8%) to 0.5%” | Raised“(0.4%) to (0.1%)” | — | — | — | — | — | — |
| Revenue Reported % Increase (Decrease) | — | New“2.6% to 4.2%” | — | — | — | — | — | — |
| Revenue Reported % Increase (Decrease) | New“0.8% to 2.4%” | — | — | — | — | — | — | — |
| GAAP EPS | New“$3.45 - $3.55” | Lowered“$3.37 - $3.44” | — | — | — | — | — | — |
| GAAP EPS | — | New“$0.80 - $0.87” | — | — | — | — | — | — |
| GAAP EPS | New“$0.80 - $0.87” | — | — | — | — | — | — | — |
| GAAP EPS - Reported % Increase (Decrease) | New“600.0% to 643.8%” | — | — | — | — | — | — | — |
| GAAP EPS Reported % Increase (Decrease) | New“88.5% to 94.0%” | Lowered“84.2% to 88.0%” | — | — | — | — | — | — |
| GAAP EPS Reported % Increase (Decrease) | — | New“116.2% to 135.1%” | — | — | — | — | — | — |
| Non-GAAP EPS | New“$4.02 - $4.12” | Narrowed“$4.04 - $4.11” | — | — | — | — | — | — |
| Non-GAAP EPS | — | New“$0.97 - $1.04” | — | — | — | — | — | — |
| Non-GAAP EPS | New“$0.98 - $1.05” | — | — | — | — | — | — | — |
| Non-GAAP EPS - Reported % Increase (Decrease) | New“5.4% to 12.9%” | — | — | — | — | — | — | — |
| Non-GAAP EPS Reported % Increase (Decrease) | New“1.5% to 4.0%” | Narrowed“2.0% to 3.8%” | — | — | — | — | — | — |
| Non-GAAP EPS Reported % Increase (Decrease) | — | New“9.0% to 16.9%” | — | — | — | — | — | — |
| Diluted shares outstanding | New“approximately 238 million” | Reiterated“approximately 238 million” | Lowered“approximately 235 million” | — | — | — | — | — |
| Impact of four fewer selling days on full-year | New“a headwind of more than 100 bps” | Reiterated“a headwind of more than 100 bps” | — | — | — | — | — | — |
| Non-GAAP tax rate | New“approximately 19.75%” | Reiterated“approximately 19.75%” | Lowered“approximately 19.5%” | — | — | — | — | — |
| Non-GAAP tax rate | New“approximately 19.75%” | Reiterated“approximately 19.75%” | — | — | — | — | — | — |
| Selling days headwind factored into | New“more than 100 bps” | — | — | — | — | — | — | — |